



Universiteit
Leiden
The Netherlands

Novel approaches in clinical development of cannabinoid drugs

Klumpers, L.E.

Citation

Klumpers, L. E. (2014, January 21). *Novel approaches in clinical development of cannabinoid drugs*. Retrieved from <https://hdl.handle.net/1887/23050>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/23050>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/23050> holds various files of this Leiden University dissertation

Author: Klumpers, Linda

Title: Novel approaches in clinical development of cannabinoid drugs

Issue Date: 2014-01-21

NOVEL APPROACHES IN CLINICAL DEVELOPMENT OF CANNABINOID DRUGS

Promotiecommissie

PROMOTORES

Prof. dr. J. M. A. van Gerven

Professor of Clinical Neuropsychopharmacology, Leiden University Medical Center and Centre for Human Drug Research

Prof. dr. A. F. Cohen

Professor of Clinical Pharmacology, Leiden University Medical Center and Centre for Human Drug Research

OVERIGE LEDEN

Prof. dr. P. H. van der Graaf

Professor of Bio-pharmaceutical Sciences, Leiden University

Dr. J. T. Tamsma

Internist and Medical Director of the Leiden University Medical Center

Prof. dr. R. F. Witkamp

Professor of Nutrition and Pharmacology, Wageningen University

DESIGN

Caroline de Lint, Voorburg (caro@delint.nl)

ACKNOWLEDGEMENTS

The publication of this thesis was financially supported by the foundation Centre for Human Drug Research, Leiden

CHAPTER I	7
Introduction to the endocannabinoid system as a target for drug development	
CHAPTER II	49
Novel Δ^9 -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects	
CHAPTER III	79
Manipulating brain connectivity with Δ^9 -tetrahydrocannabinol: a pharmacological resting state fMRI study	
CHAPTER IV	115
Surinabant, a selective CB ₁ antagonist, inhibits THC-induced central nervous system and heart rate effects in humans	
CHAPTER V	145
Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects	
CHAPTER VI	177
Pharmacokinetic/pharmacodynamic modelling and simulation of the effects of different CB ₁ antagonists on Δ^9 -tetrahydrocannabinol challenge tests in healthy volunteers	
CHAPTER VII	203
General discussion	
NEDERLANDSE SAMENVATTING / SUMMARY IN DUTCH	215
CURRICULUM VITAE	229
ACKNOWLEDGEMENTS	231
PUBLICATION LIST	232